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Langerhans Cells Activate Naive
Self-Antigen-Specific CD8 T Cells
in the Steady State
tion by bone marrow-derived APCs (Heath and Carbone,
2001; Kurts, 2000). Furthermore, transfer of low numbers
of autoreactive T cells did not cause autoimmunity in
any of the systems.
These experiments revealed the importance of bone
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312 Church Street SE marrow-derived APC in tolerance induction to self-anti-
gens and were followed by other studies showing thatMinneapolis, Minnesota 55455
dendritic cells (DC) specifically are the tolerogenic APC
(Belz et al., 2002). Targeting antigens in situ through
DEC-205 resulted in tolerance of T cells (Bonifaz et al.,Summary
2002; Hawiger et al., 2001), and injection of mice with
dying OVA-loaded splenocytes led to presentation ofTCR transgenic mice that express a peptide antigen
in keratinocytes develop a lethal CD8 T cell-dependent OVA by CD8 DC, followed by deletion of antigen-
specific T cells (Huang et al., 2000; Sauter et al., 2000).autoimmune disease. We employed an adoptive trans-
fer system to understand this disease and show that In addition, Probst et al. (2003) used inducible expres-
sion of LCMV epitopes by resting or activated DC in vivotransfer of low numbers of naive CD8 T cells into pep-
tide transgenic mice caused chronic skin disease. The and showed that DC induce immunity or tolerance, de-
pending solely on their activation status. These andantigen-presenting cell that initiated this response
was the epidermal Langerhans cell. Naive CD8 T cells other observations form the basis for the currently ac-
cepted paradigm that DC are tolerogenic when theyproliferated extensively, migrated to tissues, devel-
oped effector function, and were capable of making migrate and present self-antigen in the steady state.
When DC subsequently mature in response to infectiona recall response. These features are very different
from the abortive activation of CD8 T cells that oc- or injury, they acquire the properties necessary for im-
mune activation (Steinman and Nussenzweig, 2002).curred in response to the same antigen presented by
APC from other tissues. Furthermore, tolerance was We previously described a double transgenic mouse
model (OT-I/K14-OVAp) in which peripheral tolerance isdominant when the antigen was presented by both
Langerhans cells and other APC. These data suggest broken and 80% of animals develop lethal CD8 T cell-
dependent autoimmune disease within the first 6 weeksthat Langerhans cells do not have tolerogenic proper-
ties in the steady state. of life (McGargill et al., 2002). In those mice, a chicken
ovalbumin peptide (OVAp) was expressed under the
control of the human keratin 14 promoter, which targetsIntroduction
expression to thymus and stratified epithelial tissue,
such as the skin (McGargill et al., 2000). To address theAutoreactive T cells are eliminated during development
in the thymus (Starr et al., 2003; Stockinger, 1999). None- mechanism of autoimmunity in this model, we employed
an adoptive transfer approach similar to that used totheless, additional mechanisms of tolerance appear to
be necessary to minimize T cell reactivity to self-anti- study T cell tolerance previously. We show that Langer-
hans cells (LC), which are specialized epidermal antigen-gens expressed uniquely in the periphery. Peripheral
tolerance mechanisms can be divided into those that presenting cells, present this self-antigen in the lymph
nodes in the steady state. Surprisingly, presentation ofact directly on responding T cells such as ignorance,
anergy, and clonal deletion and those that involve other self-antigen by LC did not promote tolerance, but rather
resulted in antigen-specific CD8 T cell expansion, migra-cell subsets, such as regulatory T cells (Walker and
Abbas, 2002). tion to tissues, development of effector function, and
autoimmunity that was lethal under some circum-Several laboratories have studied T cell tolerance us-
ing transgenic mice that express self-antigen in periph- stances.
eral tissues. Adoptive transfer of TCR transgenic T cells
specific for the self-antigen was used to study the re- Results
sponse of naive T cells to self-antigen in vivo. Kurts et
al. (1996) used mice that expressed ovalbumin (OVA) in Full CD8 T Cell Activation in Response to a Self-
the pancreas and kidney. In their model, the activation Antigen Expressed under the Human K14 Promoter
and modest proliferation of antigen-specific CD8 T cells To examine the specific response of CD8 T cells to self-
was followed by deletion (Kurts et al., 1997). Tolerance antigen in the K14-OVAp model system, we employed
of autoreactive T cells was also observed in transgenic an adoptive transfer approach (Kearney et al., 1994;
models expressing influenza virus hemagglutinin as a Kurts et al., 1996), where the donor T cells could be
self-antigen in pancreas (Adler et al., 1998; Lo et al., distinguished via a congenic marker Thy1.1. Naive
1992; Morgan et al., 1999). These adoptive transfer ex- (CD44low) OT-I CD8 T cells were purified and injected
periments confirmed that antigen recognition took place into K14-OVAp or control C57BL/6 (B6) recipients that
in lymph nodes and was dependent on crosspresenta- were immunized with vaccinia virus expressing the same
OVAp epitope. At various times after adoptive transfer,
skin-draining lymph nodes and spleen were collected*Correspondence: hogqu001@gold.tc.umn.edu
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Figure 1. Robust Clonal Expansion Occurs
with Transfer of Low Numbers of OT-I CD8
Cells and Recipients Develop Alopecia and
Vitiligo
(A) 5 104 and 1 106 purified Thy1.1 CD8
OT-I T cells were transferred i.v. into K14-
OVAp and B6 mice, respectively. Half of B6
mice were infected 6 hr after adoptive trans-
fer with vacc-OVA. Clonal expansion is indi-
cated as a percent Thy1.1 cells of total CD8
T cells. Inset: number of OT-I cells remaining
in K14-OVAp and B6 mice injected with vacc-
OVA on day 21.
(B) 105 purified naive Thy1.1 CD8 OT-I
T cells were transferred i.v. into K14-OVAp
and B6 mice (data not shown). K14-OVAp re-
cipients developed skin lesions, alopecia,
and/or vitiligo. This is representative of sev-
eral independent experiments.
(C) 12 K14-OVAp and 12 control C57BL/6
mice were transferred with 105 purified naive
CD8 OT-I T cells. Mice were scored for clini-
cal symptoms over the period of 12 weeks as
described in Experimental Procedures. At the
end of 6 weeks, all recipients developed a clinical score of at least 1. The graph represents average clinical score of all recipients.
(D) Individual clinical score of 12 K14-OVAp (filled circles) and 12 control C57BL/6 (open circles) mice on day 42 is shown. Each filled circle
represents one K14-OVAp mouse, while all C57BL/6 are depicted as one open circle for clarity purposes.
and the number of OT-I cells within CD8 T cell pool was than 5  105 cells caused lethality in all recipients. The
transfer of lower numbers of OT-I T cells (5  104–1 evaluated by flow cytometry. As shown in Figure 1A,
CD8 T cells proliferated extensively in response to self- 105) resulted in the development of skin lesions, alopecia
(hair loss), and vitiligo (coat depigmentation) (Figure 1B)antigen in K14-OVAp mice. In addition, they upregulated
CD69 and CD44 and downregulated CD62L (data not that lasted for at least a 6 week period of observation
(Figure 1C). At the end of 6 weeks, all recipients devel-shown), which are classic markers of TCR activation.
Surprisingly, the magnitude of the response and accu- oped a clinical score of at least 1; however, some ani-
mals had score of 2 or 3 (Figure 1D). Extensive prolifera-mulation in lymphoid organs (Figure 1A) exceeded that
of T cells responding to vaccinia virus expressing the tion of OT-I cells in response to OVAp expressed in the
skin and the development of autoimmune disease in thesame antigen. This may be explained by competition
among OVA-specific and polyclonal CD8 T cell re- recipient mice suggested that the ovalbumin peptide
was presented in a stimulatory rather than tolerogenicsponding to vaccinia epitopes other than OVAp. Also,
OT-I cells remained present in K14-OVAp mice up to fashion.
day 21 at levels similar to mice immunized with vacc-
OVA (Figure 1A, inset). In addition, unpurified OT-I CD8 OT-I CD8 T Cells Gain Full Effector
Function in K14-OVAp MiceT cells and CD8 T cells from OT-I/RAGo mice underwent
a similar expansion in K14-OVAp hosts, suggesting that Recent findings have shown an uncoupling of prolifera-
tion and effector function during the response to self-the robust response was not due to a small population
of memory cells. This was quite distinct from the behav- antigens (Hernandez et al., 2002). Thus, the ability of
OT-I cells to perform effector function was tested in anior of naive CD8 T cells in other self-antigen model sys-
tems, which showed upregulation of activation markers in vivo killing assay. OT-I cells were transferred into
K14-OVAp or B6 control hosts. On day 6 after adoptiveand cell division, but no substantial T cell accumulation,
suggesting an “abortive” T cell activation process (Her- transfer, both recipient groups received unpulsed or
OVA-pulsed B6 spleen cells. The two cell populationsnandez et al., 2001; Kurts et al., 1997). The outcome
of the adoptive transfer correlated with the number of were differentially CFSE labeled, and the killing of OVA-
pulsed cells was assessed as a disappearance of thetransferred OT-I cells (Table 1). The transfer of more
Table 1. Adoptive Transfer of T Cell Numbers above 5  105 Is Lethal
Number of Cells Injected Day Analyzed Number of Cells Recovered %OT-I of CD8 Cells Fold Increase
5  103 5 5.00  105 0.03 100
5  104 5 1.31  107 14.6 200
5  105 5 1.23  108 27 300a
1  106 4 dead dead dead
5  106 3 dead dead dead
Various numbers of Thy1.1 CD8 OT-I T cells were transferred into K14-OVAp recipients. The number of cells recovered from pooled lymph
nodes and spleen is indicated. The results are representative of several independent experiments.
a Some of the animals in this group died within 10 days after adoptive transfer.
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In vivo cytolysis was also observed at days 16 and 21
post adoptive transfer (data not shown). CD8 T cells
from K14-OVAp hosts also secreted high levels of IFN
during an in vitro recall assay (Figure 2B). Finally, OT-I
cells were able to migrate into tissues in K14-OVAp
hosts but not B6 controls, as assessed by whole-mouse
microscopy (Supplemental Figure S1 at http://www.
immunity.com/cgi/content/full/21/3/391/DC1). It was pre-
viously reported that development of effector function
from naive CD8 T cells requires three signals: antigen,
costimulation, and a third signal in the form of IL-12
(Curtsinger et al., 2003). Using adoptive transfer of OT-I
deficient in either the IL-12R, we found that OT-I prolifer-
ation and IFN production were partially dependent on
IL-12 (Supplemental Figure S2), further indicating that
OT-I cells in K14-OVAp recipients perceive a robust anti-
genic stimulation.
The capacity of CD8 T cells to develop into memory
cells was tested next in this system. Naive OT-I CD8
T cells were adoptively transferred into K14-OVAp or
control B6 mice. After a period of 3 weeks, animals were
rechallenged with OVAp/LPS or LPS alone. As shown
in Figure 2C, OT-I cells in K14 recipients made a recall
response to OVAp/LPS and to LPS alone. In fact, the
analysis was undertaken at day 3 of the response in-
stead of day 6 since K14-OVAp recipients that were
rechallenged with OVAp/LPS experienced a lethal reac-
tion. In some experiments, the extent of proliferation in
response to LPS alone did not reach that of the response
to OVAp/LPS and the reaction was never lethal.
Taken together, these results imply that CD8 T cells
become fully activated, develop effector function, and
can make recall response when previously activated by
self-antigen from skin in the absence of overt inflamma-
tion or injury.
Self-Antigen Expressed under the Human Keratin 14
Promoter Is Presented by Langerhans CellsFigure 2. Transferred CD8 OT-I T Cells Gain Effector Function
Naive CD8 T cells are dependent on antigen-presentingAll graphs are representative of at least three independent experi-
cells for their activation. Because OT-I T cells underwentments.
proliferation and CTL differentiation in K14 recipients,(A) 5  104 Thy1.1 CD8 OT-I T cells were transferred into K14-
OVAp recipients. At day 6, the animals received target cells labeled it was important to identify what cell initiated this pro-
with CFSE. The OVA-pulsed target cells were labeled with a high found immune response to self-antigen. Analysis of CD8
level of CFSE (right peak), and the control target cells were labeled T cells 40 min after introduction in K14-OVAp recipients
with a lower level of CFSE (left peak).
showed CD69 upregulation on T cells from skin-draining(B) 5  104 Thy1.1 CD8 OT-I T cells were transferred into K14-
lymph nodes, but not spleen (data not shown), sug-OVAp or control (B6) recipients. After 6 days, lymph node and spleen
gesting that naive T cell activation occurred in lymphcells were harvested and restimulated with OVAp in vitro. Then,
cells were fixed, permeabilized, and stained intracellulary with anti- nodes draining the sites of antigen expression. There-
IFN. Only data from lymph node are shown. fore, CD11c dendritic cells were isolated either from
(C) 5  104 Thy1.1 CD8 OT-I T cells were transferred into K14- skin-draining lymph nodes or spleen of K14-OVAp and
OVAp or control B6 recipients. After 21 days, the animals were
B6 mice and incubated with OT-I cells in vitro. As shownrechallenged intravenously with OVAp  LPS or LPS alone. After 3
in Figure 3A, DC from K14 skin-draining lymph nodesdays, clonal expansion was measured. It is indicated as a number
but not from spleen were able to induce OT-I CD8of OT-I cells in the lymph nodes that are Thy1.1.
T cell proliferation.
Because only DC from skin-draining lymph nodes pre-
sented antigen to antigen-specific CD8 T cells in theseCFSEhi population by flow cytometry (Mueller et al.,
2002). While OVA-pulsed targets remained intact in B6 mice, one possibility was that secreted OVA peptide was
carried to the node via the lymphatics and presented byhosts, 98% killing efficiency was observed in K14-OVAp
mice (Figure 2A). The extent to which OT-I cells killed lymph node-residing DC (Itano et al., 2003). However,
this seemed unlikely because in vivo killing experimentstarget cells in K14-OVAp mice was comparable to killing
in B6 mice immunized with vacc-OVAp (data not shown), with Kb versus Kb target cells showed no killing of
unpulsed Kb target cells compared to Kb cells in K14-suggesting that OT-I cells were able to develop full ef-
fector function in response to self-antigen in K14-OVAp. OVAp mice, as would be expected if OVA peptide was
Immunity
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Figure 3. Langerhans Cells from K14-OVAp Mice Present Antigen to OT-I Cells In Vitro
All graphs are representative of several independent experiments.
(A) DC from lymph node were isolated and incubated with CFSE-labeled 5  104 OT-I cells in vitro for 48 hr. As a positive control, DC from
B6 mice were pulsed with 0.1 nM OVAp for 1 hr. Percent proliferation represents percent of CD8 Thy1.1 cells that have diluted CFSE.
(B) Dendritic cells were isolated from lymph nodes of K14-OVAp mice using anti-CD11c MicroBeads and magnetic separation. Purified DCs
were stained with antibodies to the following surface markers: CD205, CD11c, and CD8a. CD205CD8aint (1) represent Langerhans cells and
CD205CD8a or CD8a (2) represent the remaining lymph node DC subsets.
(C) E-cadherin-positive and -negative fractions were isolated from skin-draining lymph nodes of K14-OVAp mice as described in Experimental
Procedures. E-cadherin-positive fraction increased from 18%–20% of total CD11c cells before purification to 50%–65% of total CD11c
after purification. The quality of purification was assessed by staining of isolated populations with anti-MHC class II.
(D) Lymph node Langerhans cells from K14-OVAp were isolated using anti-E-cadherin antibody and incubated with Thy1.1 OT-I cells in vitro.
After 12 hr, CD69 upregulation on OT-I cells was assessed using flow cytometry and gating on CD8 Thy1.1 cells.
freely available in the lymph (Supplemental Figure S3). al., 2002). Therefore, dendritic cells were isolated from
the lymph nodes of K14-OVAp mice and enriched forAlternatively, skin-residing DC could capture antigen in
the epidermis and migrate to the draining lymph nodes. LC using low doses of an anti-E-cadherin antibody and
magnetic sorting. The E-cadherin-negative fraction wasTwo predominant populations of DC reside in the skin:
dermal DC and epidermal Langerhans cells (LC). Given depleted of Langerhans cells (less than 6% of cells in this
fraction were Langerhans cells), while the E-cadherin-the close proximity of Langerhans cells to the basal
keratinocytes that express antigen in this system, their positive fraction was enriched (more than 50% of
E-cadherin-positive cells were Langerhans cells) (Figurerole in OVAp presentation was tested. LC are distin-
guished from other DC subsets via their high expression 3C). Identity of Langerhans cells was assessed by ex-
pression of high levels of MHC class II, which is a reliableof CD205 and low expression of CD8 (Kamath et al.,
2002; Ruedl et al., 2000). This subset is found only in marker of lymph node Langerhans cells (Figure 3B). As
shown in Figure 3D, only unseparated dendritic cellslymph nodes that drain the skin, and not in the spleen
or mesenteric nodes (Henri et al., 2001). In addition, and the E-cadherin-positive fraction of K14-OVAp DCs
were able to induce CD69 upregulaton on CD8 OT-ILC express two antigens not found in dermal DC or
lymphoid DC—Langerin (CD207) and E-cadherin (Figure cells, while the E-cadherin-negative fraction was not. In
addition, the upregulation of CD69 induced by E-cad-3B, population 1; Borkowski et al., 1994; Valladeau et
Steady-State Activation by Skin Langerhans Cells
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Figure 4. The Efficiency of Priming in Differ-
ent Bone Marrow Chimeras Is Consistent with
a Role for Langerhans Cells
(A) Hematopoetic chimeras were established
after two rounds of irradiation and reconstitu-
tion using CD45 congenic bone marrow. After
8 weeks, LC were enriched from epidermal
sheets and analyzed by flow cytometry. Dot
plot shows CD45 staining on MHC class
II LC in skin and total lymph node.
(B) 1.5 104 purified naive Thy1.1CD8OT-I
T cells were adoptively transferred into indi-
cated chimeras. 4 days later, lymph nodes
(shown) and spleen were analyzed for the
presence of OT-I cells. Percent OT-I refers to
the percent of live OT-I cells of total CD8
cells.
(C) 1.5  106 Thy1.1 CD8 T cells were in-
jected i.v. into indicated bone marrow chime-
ras. LN Thy1.1 CD8 T cells were analyzed
6 hr later for CD69 expression.
herin-positive DCs exceeded that of unseparated DCs ability to activate CD8 T cells as they traffic to lymph
nodes in the steady state. This functional property offrom K14-OVAp mice. Experiment using CFSE dilution
as a readout of OT-I activation was also performed with LC is consistent with their phenotype (Stoitzner et al.,
2003). As shown in Figure 3B, LC express higher levelsE-cadherin-positive and -negative cells and confirmed
data obtained in CD69 downregulation experiment (data of MHC II, CD80, CD86, and CD40 in steady state than
do other DC subsets in the lymph node.not shown).
These data suggest that LC may be the predominant
APC in the K14-OVAp model system. To test this more Ubiquitous Expression of Antigen Leads
to a Dominant Tolerancerigorously, we used hematopoietic chimeras. LC are a
bone marrow-derived lineage of DC; however, they are The observation of full immune activation of CD8 T cells
in K14-OVAp mice led us to consider why this does notunique among other DC in that they are radioresistant
or can self-renew from radioresistant progenitors in the present a greater problem in terms of autoimmunity in
normal animals. One possibility is that when self-anti-skin (Merad et al., 2002). Therefore, in hematopoietic
chimeras, recipient LC remain of host origin for many gens are also expressed by other—potentially tolero-
genic—DC subsets, the tolerance dominates. To testweeks before they are replaced by bone marrow-derived
progenitors (Katz et al., 1979). We established hemato- this, we used two models where the antigenic peptide
(OVAp) was ubiquitously expressed throughout thepoietic chimeras via two rounds of irradiation and recon-
stitution with CD45 congenic bone marrow. After 8 mouse. In one strain, Act-mOVA, a membrane form of
ovalbumin, was expressed under the actin promoterweeks, LC were purified from epidermal sheets of the
skin. Analysis of these cells confirmed that LC remained (Ehst et al., 2003). In the other, an ovalbumin peptide
was expressed as a fusion protein with a viral signalpredominantly (96%) of host origin (Figure 4A). To test
antigen presentation function, we constructed chimeras sequence, under the MHC class I (Kb) promoter (Goldrath
and Bevan, 1999). The later strain represents a moreusing either B6 or bm8 mice. Bm8 mice have a mutation
in the Kb molecule such that they are not able to present direct comparison to the K14-OVAp mouse, as both
produce only a single antigenic epitope of ovalbumin,OVAp to OT-I T cells. OT-I cells were transferred into
bone marrow chimeras whose ability to present OVAp whereas Act-mOVA mice generate both MHC class I
and class II restricted epitopes. OT-I cells underwentwas limited either to LC (bm8→K14-OVAp.B6) or to bone
marrow-derived DC subsets (B6→K14-OVAp.bm8). As activation and moderate proliferation upon transfer into
both Act-mOVA and Kb-OVAp recipients, as judged byshown in Figure 4B, OT-I T cells displayed maximal
clonal expansion only in chimeras where the radioresis- CFSE dye dilution (Figure 5D and data not shown). How-
ever, in striking contrast to K14-OVAp recipients, CD8tant APC could present antigen (bm8→K14-OVAp.B6).
In chimeras where only bone marrow-derived APC could T cells did not accumulate in either recipient strain (Fig-
ures 5A and 5B). In addition, the remaining cells in Act-present the antigen, some expansion was observed (as
was CD69 upregulation, Figure 4C); however, this was mOVA mice did not respond to restimulation with OVAp/
LPS (Figure 5C) or gain cytolytic effector function (dataat least 10-fold less than in the other chimeras. Taken
together, these data suggest that LC possess a unique not shown). These findings suggest that OT-I cells un-
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Figure 5. Abortive Activation Occurs in Act-mOVA and Kk-OVAp Mice and Leads to Tolerance
All graphs are representative of several independent experiments.
(A) 5  104 Thy1.1 CD8 OT-I cells were transferred into indicated recipients. K14  mOVA stands for K14-OVAp  Act-mOVA F1 mice.
Clonal expansion is indicated as a percent Thy1.1 cells of total CD8 T cells.
(B) 5  104 Thy1.1 CD8 OT-I cells were transferred into indicated recipients. Lymph nodes and spleens were harvested on day 6 after
adoptive transfer, and total number of OT-I cells was calculated as percentage of Thy1.1 CD8 cells within live cells.
(C) 2.5  106 Thy1.1 CD8 OT-I cells were transferred into Act-mOVA or C57BL/6 mice. After 21 days, the animals were rechallanged
intravenously with OVAp  LPS or LPS alone. After 3 days, clonal expansion was measured. It is indicated as a number of CD8 cells in the
lymph nodes that are Thy1.1.
(D) 1  106 CFSE-labeled Thy1.1 CD8 OT-I cells were transferred into K14-OVAp, Act-mOVA, or B6 mice. 48 hr later, lymph nodes were
harvested and CFSE dilution was assessed by flow cytometry.
(E) Percentage of survival of double and triple transgenic mice. Mice were monitored every other day for signs of disease until 12 weeks of
age. The age at which the mice died or were euthanized due to severe disease was recorded and plotted as the percentage of mice that
were alive at each time point. The number of mice in each group is indicated in parentheses.
dergo anergy or activation-induced unresponsivness 2002). In contrast, OT-I/Act-mOVA double transgenic
mice did not develop autoimmune disease (Figure 5E).in an environment where the antigen is expressed ubiq-
uitously, as was shown previously for other models Furthermore, the ubiquitous expression of antigen pro-
tected K14-OVAp mice from lethal autoimmunity, as tri-systems (Hernandez et al., 2001; Kurts et al., 1997). Im-
portantly, OT-I T cells transferred into K14-OVAp Act- ple transgenic OT-I/K14-OVAp  Act-mOVA mice re-
mained healthy up to 12 weeks of age. This difference inmOVA F1 recipients also did not accumulate (Figure 5A),
suggesting that the tolerance induced is dominant of immunity was not due to differences in central tolerance,
since the thymic phenotype did not differ between OT-I/LC-mediated activation.
Intact OT-I/K14-OVAp double transgenic mice de- K14-OVAp and OT-I/Act-mOVA mice (Mayerova and
Hogquist, 2004). Taken together, these results imply thatvelop a severe autoimmune disease (McGargill et al.,
Steady-State Activation by Skin Langerhans Cells
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a broad expression of self-antigen renders CD8 T cells pendent of how LC are triggered to migrate to lymph
nodes, it is clear that the majority of LC in the nodesunresponsive to stimulation via the same antigen pre-
have a cell surface phenotype that is distinct from othersented by LC.
DC, as discussed above (Wilson et al., 2003). Since these
molecules are typically associated with immune respon-Discussion
siveness, the phenotype of LC in the steady state is
consistent with the functional properties we report here.Our experiments report the surprising finding that a spe-
One can imagine that the potent immunogenicity ofcialized subset of dendritic cells residing in the epider-
LC could be an essential property for APC involved inmis—Langerhans cells—present antigen to T cells in an
immunity at barrier surfaces (Blank et al., 1993; Kupperimmunogenic fashion, as they traffic to lymph nodes in
and Fuhlbrigge, 2004). Nonetheless, an APC populationthe steady state. This contrasts the current paradigm,
that is exclusively or predominantly immunogenic to na-established for other interstitial DC, that DC induce toler-
ive T cells naturally presents a challenge to the mainte-ance to self-antigens as they traffic to lymph nodes in
nance of self-tolerance. In this regard, our studiesthe steady state (Steinman and Nussenzweig, 2002).
showed that when the same self-antigen was also dis-Nonetheless, these results are consistent with some of
played by other APC in addition to LC, tolerance domi-the established properties of LC (Romani et al., 2003).
nated. Therefore, it would appear that only when LC areLC have long been appreciated to be a highly potent
the predominant or sole APC does a robust immuneAPC. As they reside in the epidermis, they have a so-
response to self-antigen occur. The question then risescalled “immature” phenotype. However, inflammation,
as to whether LC ever display self-antigens that wouldinjury, and mechanical stress trigger LC migration from
not also be presented by other DC. Since LC are anatom-the skin to the lymph node. This migration, which can
ically positioned directly among keratinocytes, it seemsbe induced by inflammatory cytokines TNF and IL-1
possible that keratinocyte antigens could be uniquely(Randolph, 2002) and is dependent on CCR2 and CCR7
displayed by LC. However, it is critical to know if LC(Saeki et al., 1999; Sato et al., 2000), is accompanied
constitutively process and present antigens from theby “maturation,” which includes a change in surface
epidermal microenvironment, for example via uptakephenotype and increase in T cell stimulatory capacity
and processing of apoptotic keratinocytes. Hemmi and(Banchereau and Steinman, 1998). In addition, data from
colleagues utilized a clever approach to address thisin vitro maturation models suggests that phagocytosis
question. Mice expressing a hepatocyte growth factorand MHC class II antigen-processing are downregu-
transgene driven by the K14 promoter have an unusuallylated, and the translocation of class II to the surface is
high level of melanocytes in the epidermis. They showedupregulated (Mellman and Steinman, 2001). Therefore,
that in such mice, melanin was associated with CD205most LC in the lymph node, where naive T cells exist,
DC in skin-draining lymph nodes and was dependenthave an activated phenotype: they are CD40-high, MHC
on TGF, strongly suggesting that LC carried it to theclass II-high, and express high levels of CD80 and CD86
nodes (Hemmi et al., 2001). However, they did not exam-(Figure 3C; Stoitzner et al., 2003). Irritation of the skin
ine MHC class I or class II presentation of antigens
can further increase the CD80 and CD40 levels, but only
derived from melanin. In fact, it was recently suggested
slightly (Stoitzner et al., 2003). Since the phenotype of
that crosspresentation by LC does not occur for class
lymph node LC in the steady state is distinctly different I antigens. Carbone and coworkers utilized a skin HSV
from that of other lymph node DC, it raises the question infection model, where the virus infects only cells in the
of whether LC that traffic to the lymph node in the steady epidermis (predominantly keratinocytes). Despite the in-
state are functionally mature or not. timate location of LC within the epidermis, LC did not
If LC migration were strictly linked to maturation, then present viral antigens to CD8 T cells in the node, while
one might predict that only mature immunogenic LC CD8 DC did (Allan et al., 2003). Although it is possible
would traffic to lymph nodes where they can interact that the lack of crosspresentation by LC could reflect
with T cells. Therefore, an important question is whether viral inhibition, recent findings in K5-mOVA transgenic
there is a “basal” migration of immature LC to the lymph mice are also consistent with a lack of crosspresenta-
node in the absence of inflammation or injury, and does tion. K5-mOVA mice express a transmembrane form of
it contribute to tolerance (Randolph, 2002)? In normal ovalbumin in keratinocytes. Analysis of bone marrow
unmanipulated mice, about 20% of lymph node DC ex- chimeras showed that predominantly marrow-derived
press Langerin (D.M. and K.A.H., unpublished observa- APC (DC), and not radio-resistant APC (LC), presented
tion). The density of LC in the epidermis is 400–900/mm2 class I antigens to CD8 T cells in these mice (Azukizawa
(Bergstresser et al., 1980), and the size of the epidermis et al., 2003). These data suggest that LC may not pro-
of a 20 g mouse was estimated at 7000 mm2 (Harkness cess and crosspresent self-antigens from keratinocytes
and Wagner, 1989). Thus, in the steady state, we esti- via the class I pathway in the steady state. Our ability
mate that 3%–8% of all LC in the mouse are present in to see LC presentation of a keratinocyte-derived class
lymph nodes. Does this population represent a basal I antigen in this system therefore may reflect the fact that
circulation of LC through the lymph, or does it represent the K14-OVAp transgene encoded a peptide minigene,
LC that were induced to migrate via everyday mechani- which could be secreted and bound to MHC class I
cal stress (scratching) and/or subclinical microbial infec- molecules on adjacent LC. Nonetheless, this feature al-
tions? While some research suggests an independent lowed us to study T cell immunity to an antigen ex-
basal migration pathway (Yoshino et al., 2003), more pressed exclusively by LC. Further experiments are
needed to rigorously test the issue of whether LC nor-data are needed to address this issue definitively. Inde-
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behind the early/late P7.5 promotor of vaccinia. This minigene con-mally are the exclusive presenter of epidermal self-anti-
sists of two parts—a signal sequence (JAW) and OVA papetide.gens and to ask if such presentation is regulated by
injury or inflammation to the skin.
T Cell Adoptive TransferOne clinical situation of potential relevance is alloge-
OT-I CD8 T cells were isolated from lymph nodes of OT-I/Thy1.1neic bone marrow transplantion. Here, the radio-resis-
mice and purified by negative selection using magnetic cell sortingtant LC present a unique set of alloantigens compared
MACS (Miltenyi Biotec, Auburn, CA) as previously described (Prlic
to the bone marrow-derived DC. Therefore, the lack of et al., 2001). To purify CD44 low T cell, cell suspension was labeled
tolerogenicity by LC might be a factor, particularly in with FITC-coupled Abs to B220, I-Ab, CD4, and CD44 (0.0125 g
the CD8 T cell-mediated cutaneous graft-versus-host anti-B220 and anti-I-Ab per 1  106 cells; 0.004 g anti-CD44 per
1  10 cells) (all from BD PharMingen, San Diego, CA). Followingdisease often observed in such patients.
staining, cells were subject to depletion using anti-FITC MACS mi-K14-OVAp mice provide evidence that LC do not in-
crobeads. Cell purity (90%) was established by flow cytometry.duce tolerance to self-antigen as they traffic to lymph
Purified Thy1.1 CD44lo CD8 OT-I T cells were injected into the tail
nodes in the steady state. Nonetheless, many studies vain of recipient mice. At various times after injection, single-cell
have shown LC to be capable of inducing tolerance. suspensions from skin-draining lymph nodes or spleen were stained
Interestingly, these experiments predominantly involve with PerCP-labeled anti-Thy1.1, APC-labeled anti-CD8 (both from
BD PharMingen) to detect transferred cells. Data were collectedUV irradiation of the skin (Lucas and MacPherson, 2002).
using a FACSCalibur (BD Biosciences, San Jose, CA) and analyzedUV irradiation is a strong stimulus for LC migration, and
with FlowJo software (TreeStar, San Carlos, CA). The number ofin fact can cause local depletion of the LC network.
OT-I T cells in lymph nodes and spleen was calculated by multiplying
Antigens that are coadministered with UV irradiation can the percentage of Thy1.1 CD8 cells by number of viable cells
induce a dominant tolerance, suggested to be the result as determined by trypan blue dye exclusion. Three animals per
of the generation of CD4CD25 T regulatory cells experimental group were used. The number of OT-I cells was as-
sessed for each mouse and an average number of OT-I cells from(Schwarz et al., 2004). The fact that UV irradiation of the
three animals was graphed.skin is required to generate immunological tolerance to
LC-presented antigens also suggests that such mecha-
Clinical Scorenisms do not occur in the steady state. The K14-OVAp
105 CD44lo CD8 OT-I cells were transferred i.v. into 12 K14-OVApmodel may represent a useful tool to further study
or 12 C57BL/6 mice. A clinical score was evaluated over time—onewhether class I antigens specifically are tolerized by
point for each of the following: vitiligo (coat depigmentation), skin
UV irradiation. lesions (abrasion), alopecia (hair loss), eye involvement (inflamma-
In summary, our results provide compelling evidence tion, corneal scarring), and hunched appearance. Maximal possible
that Langerhans cells are a unique subset of DC in that score for individual mouse was 5.
they do not induce tolerance to self-antigens as they
traffic to lymph nodes in the steady state. This work In Vivo Killing Assay
raises questions about the steady state versus active A single-cell suspension of C57BL/6 spleen cells was divided into
two. One sample was pulsed with 0.2 M OVAp (SIINFEKL) for 45trafficking of LC, as well as the crosspresenting function
min at 37	C, washed, and labeled with a high concentration (1.5of LC, which will require further study.
M) of CFSE (Molecular Probes, Eugene, OR). The other sample
was incubated without peptide at 37	C for 45 min, washed, and
labeled with a low concentration (0.05 M) of CFSE. Equal numbersExperimental Procedures
of CFSEhigh and CFSElow cells were mixed together, and 2  107
mixed cells were injected i.v. into recipients that had been previouslyAnimals
transferred with Thy1.1CD8 OT-I cells. After 3 hr, mice were sacri-C57BL/6 (B6) and Thy1.1 congenic C57BL/6.PL mice were obtained
ficed and lymph nodes and spleen cells were analyzed by flowfrom The Jackson Laboratory (Bar Harbor, ME). OT-I mice express
cytometry to detect CFSE-labeled cells.a transgenic receptor specific for the OVA 257–264 peptide (OVAp)
in the context of the H-2Kb (Hogquist et al., 1994). Transgenic strain
expressing OT-I target antigens under the control of the human Intracellular Cytokine Staining Following In Vitro Rechallenge
keratin 14 promoter was generated as described (McGargill et al., 5  104 CD44lo CD8 OT-I/PL cells were transferred i.v. K14-OVAp
2002; Stefanski et al., 2001). They are referred to as K14-OVAp. Act- or C57BL/6 mice. Lymph node and spleen cells were incubated in
mOVA mice were obtained from B. Ehst and M. Jenkins (University RPMI  10% FCS with 2 M OVAp. After 2 hr of incubation, 1 l/ml
of Minnesota, Minneapolis, MN). These mice express a transmem- of GolgiPlug (BD PharMingen) was added and cells were incubated
brane form of OVA under control of the actin promoter and CMV for additional 4 hr at 37	C. Cells were washed and stained with anti-
immediate-early enhancer (Ehst et al., 2003). Mice expressing OVAp CD8 and anti-Thy1.1 antibodies to mark the OT-I/PL cells. Cells
preceded by an endoplasmic reticulum signal sequence (SS) under were fixed in Cytofix/Cytoperm solution for 20 min at 4	C before
the control of MHC class promoter were provided by A. Goldrath staining with PE-conjugated antibody to IFN (eBioscience, San
and M. Bevan (University of Washington, Seattle, WA) (Goldrath and Diego, CA) for 30 min at 4	C. Cells were washed in Perm/Wash
Bevan, 1999). They are referred to as Kb-OVA. B6.C-H-2bm8 (bm8) solution and resuspended in FACS buffer. Data were collected on
mice were generous gifts from J. Nikolic-Zugic (Sloan-Kettering In- a FACSCalibur (BD Biosciences) and analyzed with FlowJo soft-
stitute, New York, NY) and N. Gascoigne (Scripps Institute, La Jolla, ware (TreeStar).
CA). IL-12R//OT-I mice were obtained from M. Mescher (University
of Minnesota, Minneapolis, MN). All mice were treated in accordance
In Vivo Recall Responsewith federal guidelines approved by the University of Minnesota
5  104 Thy1.1CD8 naive OT-I cells were transferred into K14-Institutional Animal Care.
OVAp or control C57BL/6 recipients. After 21 days, the animals were
intravenously injected with OVAp  LPS (10 g and 50 g/mouse,
respectively) or LPS (50g/mouse) alone. After 3 days, clonal expan-Recombinant Vaccina Virus
Recombinant vaccinia virus (rVV) expressing OVAp as a minigene sion was measured by flow cytometry. The number of OT-I T cells
in lymph nodes and spleen was calculated by multiplying the per-was generously provided by J. Yewdell (Laboratory of Viral Diseases,
National Institute of Allergy and Infectious Diseases, NIH). This re- centage of Thy1.1 CD8 cells by number of viable cells as deter-
mined by trypan blue dye exclusion.combinant virus has been modified so that the gene was introduced
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Dendritic Cell Purification and In Vitro Stimulation genically expressed in keratinocytes. Eur. J. Immunol. 33, 1879–
1888.DC from lymph node or spleen were prepared by digestion with
collagenase D (Sigma, Saint Louis, MO) and EDTA as previously Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the
described (Vremec et al., 1992). Cells were then labeled using MACS control of immunity. Nature 392, 245–252.
anti-CD11c MicroBeads (Miltenyi Biotech) and passed over a mag-
Belz, G.T., Behrens, G.M., Smith, C.M., Miller, J.F., Jones, C., Lejon,
netized MACS selection column.
K., Fathman, C.G., Mueller, S.N., Shortman, K., Carmone, F.R., and
Alternatively, cells were labeled with anti-Thy1.1 bio (eBio-
Heath, W.R. (2002). The CD8alpha() dendritic cell is responsible
science), anti-NK1.1 bio, anti-CD45R bio (BD PharMingen), and
for inducing peripheral self-tolerance to tissue-associated antigens.
anti-F4/80 bio (Sigma), followed by incubation with MACS SA Mi-
J. Exp. Med. 196, 1099.
croBeads (Miltenyi Biotech). After washing the column, the unla-
Bergstresser, P.R., Fletcher, C.R., and Streilein, J.W. (1980). Surfacebeled cells were collected. Aliquot was stained with anti-CD11c
densities of Langerhans cells in relation to rodent epidermal sites(BD PharMingen), and the purity of the cells was assessed by flow
with special immunologic properties. J. Invest. Dermatol. 74, 77–80.cytometry. Remaining DCs were stained with 1:400 dilution of anti-
E-cadherin antibody, followed by incubation with goat-anti rat IgG Blank, C., Fuchs, H., Rappersberger, K., Rollinghoff, M., and Moll,
bio (BD PharMingen). Cells were then incubated with MACS SA H. (1993). Parasitism of epidermal Langerhans cells in experimental
MicroBeads (Miltenyi Biotech), and positive and negative fractions cutaneous leishmaniasis with Leishmania major. J. Infect. Dis.
were collected from the column. Purified DCs were serially diluted 167, 418–425.
in RPMI 10% FCS and incubated with CFSE-labeled Thy1.1 OT-I Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M.C.,
cells cells in vitro for 48 hr. As a positive control, B6 DC were pulsed and Steinman, R.M. (2002). Efficient targeting of protein antigen to
with 0.1 nM OVAp for 1 hr. Percent proliferation represents percent the dendritic cell receptor DEC-205 in the steady state leads to
of CD8 Thy1.1 cells that have diluted CFSE. antigen presentation on major histocompatibility complex class I
For phenotypic characterization, DCs were stained with FITC- products and peripheral CD8 T cell tolerance. J. Exp. Med. 196,
coupled antibody to CD205 (Serotec, Oxford, UK), PE-coupled 1627–1638.
antibody to CD11c, PerCP-coupled antibody to CD8 (both BD Pha-
Borkowski, T.A., Van Dyke, B.J., Schwarzenberger, K., McFarland,
rMingen), and biotin-labeled antibody to CD80, CD86, CD40 (all
V.W., Farr, A.G., and Udey, M.C. (1994). Expression of E-cadherin by
eBioscience), purified anti-E-cadherin (Sigma). Some DCs were also
murine dendritic cells: E-cadherin as a dendritic cell differentiation
stained for intracellular Langerin using an antibody (929F3, provided
antigen characteristic of epidermal Langerhans cells and related
by Dr. Sem Saeland) as previously described (Stoitzner et al., 2003).
cells. Eur. J. Immunol. 24, 2767–2774.
Goat-anti-rat IgG (BD PharMingen) was used as secondary antibody
Borkowski, T.A., Letterio, J.J., Mackall, C.L., Saitoh, A., Wang, X.J.,for E-cadherin and Langerin.
Roop, D.R., Gress, R.E., and Udey, M.C. (1997). A role for TGFbeta1
in langerhans cell biology. Further characterization of the epidermalPreparation of Epidermal Cell Suspension
Langerhans cell defect in TGFbeta1 null mice. J. Clin. Invest. 100,Epidermal cells suspension was prepared form trunk skin by limited
575–581.trypsinization and dissociation of epidermal sheets by pipetting in
DNase as previously described (Borkowski et al., 1997). Cells were Curtsinger, J.M., Lins, D.C., and Mescher, M.F. (2003). Signal 3 deter-
then labeled using MACS anti-MHC class II MicroBeads (Miltenyi mines tolerance versus full activation of naive CD8 T cells: dissociat-
Biotech) and passed over a magnetized MACS selection column to ing proliferation and development of effector function. J. Exp. Med.
enrich for Langerhans cells. Cells were then stained for surface 197, 1141–1151.
CD45.1, CD45.2, CD11c, and MHC class II (all BD PharMingen) and Ehst, B.D., Ingulli, E., and Jenkins, M.K. (2003). Development of a
analyzed by flow cytometry. novel transgenic mouse for the study of interactions between CD4
and CD8 T cells during graft rejection. Am. J. Transplant. 3, 1355–
Bone Morrow Chimeras 1362.
Single-cell bone marrow suspensions from C57BL/6 or B6.C-H-
Goldrath, A.W., and Bevan, M.J. (1999). Low-affinity ligands for the
2bm8 mice were prepared and depleted of mature T cells by com-
TCR drive proliferation of mature CD8T cells in lymphopenic hosts.
plement-mediated cytotoxicity using 30H12 (anti-Thy1.2; ATCC,
Immunity 11, 183–190.
Manassas, VA) as described (Nikolic-Zugic and Bevan, 1988). Bone
Harkness, J.E., and Wagner, J.E. (1989). The Biology and Medicinemarrow cells were then injected i.v. (107 cells/recipient) into lethally
of Rabbits and Rodents, 3rd edn (Philadelphia: Lea & Febiger).irradiated recipient mice (900 rads).
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